TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32038628
Drug: Nadolol (β1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (β1 + β2‐AR antagonist)
Study: 32038628
Drug: Bisoprolol (β1‐AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (β1‐AR antagonist)
Study: 32991794
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg mRNA-1273 vaccine
Study: 32991794
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg mRNA-1273 vaccine
Study: 32991794
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine (both doses)
Study: 36088426
Drug: Histology-tailored chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histology-tailored chemotherapy regimen
Study: 35427481
Drug: EV71vac (aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71vac (aluminium phosphate‐adjuvanted inactivated EV71 vaccine), administered as two doses via intramuscular injection 56 days apart, with a third booster dose for children aged 2-23 months on day 366.
Study: 35427481
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as two doses via intramuscular injection 56 days apart.
Study: 35427481
Drug: EV71vac (aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71vac (aluminium phosphate‐adjuvanted inactivated EV71 vaccine)
Study: 32115719
Drug: HIV-1 genotypic
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 genotypic characteristics and transmitted drug resistance surveillance
Study: 34718635
Drug: 100 g,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g, 200 g, 300 g whole beetroot (BR)
Study: 34718635
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g whole beetroot (BR)
Study: 34718635
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g whole beetroot (BR)
Study: 34718635
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate (1000 mg)
Study: 33781913
Drug: ChAd63-KH vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd63-KH vaccine (1 × 10^10 viral particles for adults, 7.5 × 10^10 viral particles for adults and adolescents)
Study: 39253357
Drug: ChAd63-KH vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd63-KH vaccine
Study: 32806711
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of Leucine-Enriched Essential Amino Acids (LEAA)
Study: 35178112
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MTT and RVP
Study: 32790196
Drug: High-dose teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose teriparatide (40 μg)
Study: 32790196
Drug: Standard-dose teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose teriparatide (20 μg)
Study: 33826563
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) at a new dosing regimen (10 mg/kg load, 5 mg/kg/h infusion)
Study: 33003132
Drug: McGrath MAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: McGrath MAC (McG)
Study: 32748570
Drug: Lafenta transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafenta transdermal fentanyl patch (11.0 mg)
Study: 35756957
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I therapy alone
Study: 34333190
Drug: Japanese cedar
Normalized name: Japanese cedar pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese cedar pollen sublingual immunotherapy (SLIT) tablets (5000 Japanese Allergy Units)
Study: 35345248
Drug: Potent P2Y12
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent P2Y12 inhibitors
Study: 33631141
Drug: Solriamfetol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 300 mg/d
Study: 34191352
Drug: Solriamfetol 75
Normalized name: solriamfetol 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 75 mg/d, 150 mg/d, 300 mg/d
Study: 33631141
Drug: Solriamfetol 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 37.5 mg/d
Study: 33631141
Drug: Solriamfetol 75
Normalized name: solriamfetol 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 75 mg/d
Study: 33631141
Drug: Solriamfetol 150
Normalized name: solriamfetol 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 150 mg/d
Study: 36084494
Drug: Solriamfetol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (all doses combined)
Study: 33318635
Drug: AV-101 (1440
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (1440 mg)
Study: 33318635
Drug: AV-101 (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (720 mg)
Study: 33318635
Drug: AV-101 (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (720 mg and 1440 mg)
Study: 35358462
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of next-generation hormonal drug
Study: 32487213
Drug: Post-operative placebo
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative placebo therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Study: 32487213
Drug: Post-operative antibiotic
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative antibiotic therapy (ceftriaxone 2 g/24 h and metronidazole 1500 mg/24 h for 3 days)
Study: 32438531
Drug: Intermittent fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent fasting (IF) with 100% or 70% of calculated weekly energy requirements for 8 weeks
Study: 36195542
Drug: Volanesorsen, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volanesorsen, 300 mg weekly for 16 weeks
Study: 36195542
Drug: Volanesorsen, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volanesorsen, 300 mg weekly for 32-52 weeks
Study: 34837510
Drug: High-dose 131I-mIBG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 131I-mIBG therapy (666 MBq/kg)
Study: 34837510
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose chemotherapy (HDC)
Study: 32578488
Drug: Capsifen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsifen (200 mg × 1/day, 4 mg capsaicinoids/day)
Study: 34972765
Drug: Benznidazole (BZN)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BZN) and Nifurtimox (NFX) chemotherapy regimens
Study: 32345375
Drug: Intervention program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention program consisting of detecting symptoms of mental illness, strengthening parenting skills using the Circle of Security Parenting program, supporting breastfeeding, and organizing treatment pathways.
Study: 35575051
Drug: Fractional-dose IPV
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional-dose IPV (fIPV, one-fifth of IPV) - 1 dose
Study: 35575051
Drug: Fractional-dose IPV
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional-dose IPV (fIPV, one-fifth of IPV) - 2 doses
Study: 35575051
Drug: Full-dose IPV
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose IPV
Study: 35575051
Drug: Full-dose IPV
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose IPV - 2 doses
Study: 33609248
Drug: Venetoclax in
Normalized name: Product containing venetoclax in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax in combination with azacitidine
Study: 33609248
Drug: Ongoing clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing clinical trials with low- and high-intensity therapies
Study: 32448020
Drug: riluzole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: riluzole (50 mg)
Study: 34800079
Drug: Patiromer (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (titrated up to a maximum of three packs/day, 8.4 g/pack)
Study: 34563120
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) exercises based on Xbox Kinect, 2 sessions of 30-45 minutes weekly for 6 weeks
Study: 37415648
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy (CT)
Study: 32790066
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg glasdegib
Study: 32790066
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg glasdegib
Study: 35753072
Drug: High Intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity Interval Training (HIIT) four times weekly (EX; n=20)
Study: 32947383
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine 10% plus levofloxacin 0.5% at 1 hour preoperatively
Study: 33637837
Drug: Predictive algorithm
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive algorithm guided treatment
Study: 34616464
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg) for two weeks at 10 PM
Study: 34666693
Drug: UV irradiation
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV irradiation (half-body UV irradiation, twice weekly over 6 months at one standard erythema dose)
Study: 33546739
Drug: Baricitinib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (4 mg once daily, can be reduced to 2 mg) for 5-7 days
Study: 33546739
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (including antibiotics, thromboembolic prophylaxis, and possibly remdesivir)
Study: 36071262
Drug: Metformin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin as an adjunct to antidepressants
Study: 32044695
Drug: Balance specific
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance specific physiotherapy (Motor Program Activating Therapy in Czech cohort and Sensory-motor Integration Training in Italian cohort)
Study: 39717452
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) injection
Study: 34459702
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 every 8 weeks for 2 years (arm B)
Study: 34243616
Drug: Intravenous fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fixed-dose combination (FDC) of acetaminophen 1000 mg + ibuprofen 300 mg administered 6-hourly as a 5 min infusion for 48 hours to 5 days
Study: 32797236
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (40 μg)
Study: 32043426
Drug: arthroscopic microfracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: arthroscopic microfracture plus intra‐articular injection of HA and haMPCs
Study: 32043426
Drug: arthroscopic microfracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: arthroscopic microfracture and intra‐articular injection of HA
Study: 32043426
Drug: arthroscopic microfracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: arthroscopic microfracture group and normal saline injection
Study: 34474267
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous (IV) metoclopramide
Study: 34474267
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous (IV) ketorolac
Study: 616121600
Drug: Idebenone (Raxone)
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Idebenone (Raxone) 150 mg tablets
Study: 34557985
Drug: OTee HORSPLAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTee HORSPLAY (occupational therapy in an equine environment) for 10 weeks
Study: 34557985
Drug: OTee HORSPLAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTee HORSPLAY (occupational therapy in an equine environment)
Study: 34557985
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control condition (occupational therapy in a garden)
Study: 34006542
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 mg subcutaneous injection)
Study: 36125055
Drug: Initial oral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial oral antipsychotic (OAP) switched to PP after 9 months (OAP-PP)
Study: 35698094
Drug: Weekly screening
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly screening + symptomatic testing
Study: 33476593
Drug: Nivolumab (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (360 mg intravenously every 3 weeks) plus ipilimumab (1 mg/kg intravenously every 6 weeks) combined with histology-based, platinum doublet chemotherapy (intravenously every 3 weeks for two cycles)
Study: 33476593
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab with two cycles of chemotherapy
Study: 33476593
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (every 3 weeks for four cycles)
Study: 32169403
Drug: Citalopram added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram added to clinician-determined antipsychotic treatment
Study: 33721696
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (5.0 μg)
Study: 32251031
Drug: Intrathecal Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Morphine
Study: 32434243
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with 160 mg trimethoprim combined with 800 mg sulfamethoxazole three times a week for 12 months (placebo-controlled double-blind study)
Study: 33966329
Drug: Prediction equations
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction equations for estimating body weight in females aged 65-79 years using height, MUAC, WC, CC, and TST.
Study: 33966329
Drug: Prediction equations
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction equations for estimating body weight in females aged ≥ 80 years using height, MUAC, WC, CC, and TST.
Study: 33966329
Drug: Prediction equations
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction equations for estimating body weight in males aged 65-79 years using height, MUAC, WC, CC, and TST.
Study: 33966329
Drug: Prediction equations
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction equations for estimating body weight in males aged ≥ 80 years using height, MUAC, WC, CC, and TST.
Study: 34959148
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg misoprostol
Study: 32046747
Drug: Pycnogenol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol supplementation of 150 mg for 10 days
Study: 33021477
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg subcutaneous injection
Study: 35796769
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual informed by autofluorescence imaging
Study: 35796769
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual alone (control)
Study: 34374108
Drug: Duloxetine 60mg
Normalized name: DULOXETINE 60MG CAP,SPRINKLE,EC
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 60mg daily for 6 weeks (5 weeks full dose and 1 week taper)
Study: 32165813
Drug: Graded Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded Activity with Daily-Monitored-Walking (GAMW)
Study: 34444779
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (500 mL/d; 27% cranberry juice)
Study: 34424347
Drug: Vaginal hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal hysterectomy with apical suspension (VH)
Study: 38934231
Drug: Control/delayed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/delayed treatment group
Study: 34358471
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg daily
Study: 32077553
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of IV acetaminophen + 1 mg of IV hydromorphone
Study: 32077553
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 1 mg of IV hydromorphone
Study: 34318607
Drug: Sovesudil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovesudil (both doses)
Study: 34632925
Drug: Dolcanatide 27
Normalized name: Dolcanatide
DrugBank: Dolcanatide (DB13112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolcanatide 27 mg daily for 7 days
Study: 32056528
Drug: 70% sterile
Normalized name: ALCOHOL,ISOPROPYL 70% STERILE LIQ,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% sterile honey‐based ophthalmic formulation
Study: 32056528
Drug: 0.3% ophthalmic
Normalized name: Zymar 0.3% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ophthalmic ciprofloxacin
Study: 33080740
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine at 1.5 mg/kg
Study: 34407441
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (NSO) 500 mg twice daily for 10 days
Study: 34800794
Drug: dHACM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: dHACM Injection
Study: 33798297
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (TEAS + epidural)
Study: 33825333
Drug: Foam and
Normalized name: Proshield Foam and Spray Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foam and cream for rosacea patients (verum)
Study: 32078025
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of body-focused repetitive behaviors
Study: 32178526
Drug: DPI (rivaroxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily)
Study: 36327436
Drug: HTD1801 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 500 mg BID
Study: 36327436
Drug: HTD1801 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 1000 mg BID
Study: 32151562
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg lactoferrin
Study: 32151562
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lactoferrin
Study: 34752990
Drug: Humane treatment
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Humane treatment behaviors
Study: 33607121
Drug: Preparation time
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation time ≥10 minutes
Study: 33092501
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered via continuous intravenous infusion at a dosage of 90 μg/kg
Study: 33096120
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice group (GJG) consuming 400 ml of grape juice per day for 1 month
Study: 33096120
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and exercise group (PLEG) with concurrent physical training
Study: 33096120
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice and exercise group (GJEG) with concurrent physical training
Study: 33426861
Drug: No add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: No add-on treatment (Group B).
Study: 34158057
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin treatment
Study: 34582657
Drug: Zinc Supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc Supplement (45 mg of elemental zinc for 12 weeks)
Study: 33883008
Drug: HTL0018318 (15–35
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0018318 (15–35 mg/day)
Study: 34174217
Drug: High-dose pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pitavastatin 4mg
Study: 34174217
Drug: Low-dose pitavastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pitavastatin 1mg
Study: 33439266
Drug: Prostate radiation
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate radiation therapy (PRT) added to androgen deprivation therapy (ADT)
Study: 38462613
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant (IDI)
Study: 32173165
Drug: Cartoon-assisted preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cartoon-assisted preparation package for endoscopy
Study: 35357323
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment that tailored complexity parameters based on participants' self-reported capabilities and goals
Study: 35357323
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with complexity parameters set generically based on national guidelines
Study: 33141936
Drug: Low-trigger transfusion
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-trigger transfusion (haemoglobin below 8.0 g/dL)